Global expansion leveraging sales channels in Japan, the US and Europe
First written in FY2017-Q1. 14 of 27 entries say "Restated". Latest entry: 2026-07-27.
96 other companies' latest entry also says "Advanced".
- 2026-07-27AdvancedBusiness Alliances
「Using WEIPU's sales and customer network in China, we will provide clinical-use iPS cells manufactured using our proprietary RNA reprogramming technology, as well as clinical-use cell products such as iPS cell-derived mesenchymal stem cells (iMSCs).」
The collaboration with WEIPU, which has a sales and customer network in China, gave concrete form to a sales channel in the Chinese market for clinical-use iPS cells and related products. - FY2026-H1RestatedAnnual report
「We aim to secure stable earnings by deploying highly competitive products and services globally.」
The Company has reaffirmed its policy of deploying highly competitive products and services globally. - FY2025AdvancedAnnual report
「In February 2025, Gameto Inc. of the United States, which is supplied with the clinical-use iPSC "StemRNA™ Clinical iPSC Seed Clone" by the Group, obtained Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its "Fertilo" in vitro oocyte maturation technology using the iPSCs to conduct Phase III clinical trials.」
U.S.-based Gameto obtained FDA IND clearance for Phase III clinical trials of its technology using the clinical-use iPSCs supplied by the Company, advancing the clinical development stage of cells deployed overseas. - FY2025-H1AdvancedAnnual report
「In July 2024, we launched iPS cell-derived exosomes and entered into an agreement appointing JTB Corporation (hereinafter, "JTB") as the exclusive distributor.」
Established a new sales channel for iPSC-derived exosomes with JTB as the exclusive distributor, and developed plans for sales expansion leveraging its global network. - FY2024-Q3AdvancedAnnual report
「In December 2023, we entered into a distributorship agreement with Preci (Ukraine) and began selling primary human hepatocytes in Japan. We also entered into a worldwide distributorship agreement with Nippi and sell MatriMix(511).」
The company concretely expanded its sales channels and markets by beginning domestic sales of primary human hepatocytes under a distributorship agreement with Preci and entering into a worldwide distributorship agreement with Nippi. - FY2024-Q2RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its global expansion policy of rolling out highly competitive products and services worldwide and making them a short- to medium-term revenue pillar. - FY2024-Q1RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its global expansion policy of rolling out highly competitive products and services worldwide and making them a short- to medium-term source of revenue. - FY2023-Q3AdvancedAnnual report
「In October 2022, we entered into a business partnership with JTB Corporation concerning sales expansion targeting domestic customers and visitors to Japan.」
Regarding sales expansion for Personal iPS and other products, the company entered into a business partnership with JTB targeting domestic customers and visitors to Japan, concretely expanding its sales channels. - FY2023-Q2RestatedAnnual report
「We are rolling out highly competitive products and services worldwide and promoting them as short- to medium-term revenue pillars.」
The company has reaffirmed its global expansion policy of rolling out highly competitive products and services worldwide and making them a short- to medium-term source of revenue. - FY2023-Q1RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its global expansion policy of rolling out highly competitive products and services worldwide and making them a short- to medium-term revenue base. - FY2022-Q3RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its global expansion policy of rolling out highly competitive products and services worldwide and making them a short- to medium-term source of revenue. - FY2022-Q1RestatedAnnual report
「We are rolling out highly competitive products and services worldwide and promoting them as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out highly competitive products and services worldwide and making them a short- to medium-term source of revenue. - FY2021RestatedAnnual report
「By covering four sites in Japan, the United States, Europe and India, including the United States, the largest market in the biotechnology industry, Europe, the next-largest market, and India, the world's second-most populous country, in addition to the Japanese market, we can access many of our target customers worldwide, including universities, public research institutions and pharmaceutical companies.」
The company has reaffirmed its global expansion policy of using four sites in Japan, the United States, Europe and India to cross-sell products and services from each region. - FY2021-Q3RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its global expansion policy of rolling out highly competitive products and services worldwide and making them a short- to medium-term revenue pillar. - FY2021-Q2RestatedAnnual report
「We are rolling out highly competitive products and services worldwide and promoting them as short- to medium-term revenue pillars.」
The company has reaffirmed its global expansion policy of making the rollout of products and services in regions worldwide a short- to medium-term revenue base. - FY2021-Q1RestatedAnnual report
「We are rolling out highly competitive products and services worldwide and promoting them as short- to medium-term revenue pillars.」
The company has reaffirmed its global expansion policy of rolling out products and services worldwide and making the Research Support Business a short- to medium-term revenue pillar. - FY2020RestatedAnnual report
「By covering four sites in Japan, the United States, Europe and India, including the United States, the largest market in the biotechnology industry, Europe, the next-largest market, and India, the world's second-most populous country, in addition to the Japanese market, we can access many of our target customers worldwide, including universities, public research institutions and pharmaceutical companies.」
The company has reaffirmed its policy of continuing global expansion using four sites in Japan, the United States, Europe and India, together with cross-regional sales of products and services. - FY2020-Q2AdvancedAnnual report
「During the cumulative six-month period of the current fiscal year, we entered into a distributorship agreement with Axion BioSystems, Inc. (United States) for its cell potential measurement systems in Japan, as well as a distributorship agreement with NeuCyte, Inc. (United States) for its human iPS cell-derived neurons in North America and Europe. Adding these products further expanded our iPS cell product portfolio.」
The company entered into distributorship agreements with two U.S. companies, expanding its product portfolio and sales channels in Japan, North America and Europe. - FY2019-Q3RestatedAnnual report
「In this way, we are actively expanding our business both geographically and technologically. Geographically, we now have four sites, adding India to our existing sites in Japan, the United States and Europe. Technologically, in addition to iPS cell technology, human cell sourcing capabilities and drug discovery screening technology, we have newly introduced gene modification technology and next-generation sequencing technology.」
The company has reaffirmed its global expansion policy through operations at four sites in Japan, the United States, Europe and India, together with the introduction of gene modification and next-generation sequencing technologies. - FY2019-Q2AdvancedAnnual report
「In this way, we are actively expanding our business both geographically and technologically. Geographically, we now have four sites, adding India to our existing sites in Japan, the United States and Europe. Technologically, in addition to iPS cell technology, human cell sourcing capabilities and drug discovery screening technology, we have newly introduced gene modification technology and next-generation sequencing technology.」
The company states that it expanded its global operating footprint to four sites, including India, and newly introduced gene modification and next-generation sequencing technologies. - FY2019-Q1AdvancedAnnual report
「In June, we were selected as a J-Startup company, receiving intensive public-private support under the Ministry of Economy, Trade and Industry's J-Startup startup support program. Following this selection, we will continue to actively advance our businesses, including global expansion, the Research Support Business and the Medical Business.」
The selection as a J-Startup company represents progress in the structure for continuing to advance the business, including global expansion. - FY2018AdvancedAnnual report
「Through this acquisition of shares, our Group will expand its global operations into India, provide higher-value-added drug discovery support services and accelerate our business.」
To expand its business in India, the company acquired shares in Bioserve Biotechnologies India on 26 April 2018, making it a subsidiary in which it held 98.28% of the voting rights. - FY2018-Q3AdvancedAnnual report
「During the cumulative nine-month period of the current fiscal year, we entered into a partnership agreement with U.S.-based Science Exchange to promote the global expansion of our drug discovery support services. Going forward, we will accelerate the expansion while making further use of Science Exchange's customer base.」
To expand its drug discovery support services globally, the company entered into a partnership agreement with U.S.-based Science Exchange and began specific sales and expansion initiatives leveraging the company's customer base. - FY2017AdvancedAnnual report
「Through the acquisition of overseas subsidiaries and sales partnerships with overseas distributors, we have actively advanced global expansion and have achieved a level of globalization in which overseas markets now account for approximately 70% of consolidated net sales.」
As a result of acquiring overseas subsidiaries and entering into sales partnerships, overseas markets accounted for approximately 70% of consolidated net sales. - FY2017-Q3RestatedAnnual report
「We are developing the sales infrastructure needed for global expansion.」
The company continues to develop its sales infrastructure for global expansion. - FY2017-Q2AdvancedAnnual report
「In addition to expanding our sales network through a sales partnership with Shimadzu (Hong Kong) Limited in China, we began sales in the United States through our Group company ReproCELL USA.」
In addition to expanding the sales network through a sales partnership in China, specific initiatives progressed, including the launch of sales of StemFit Basic02 in the United States. - FY2017-Q1First statedAnnual report
「We are advancing global expansion through cross-selling the products of Group companies, leveraging a worldwide sales network spanning Japan, the United States and Europe.」
The company explicitly identifies its global sales network and cross-selling of Group products as growth drivers. In China, it also entered into a sales partnership with Shimadzu (Hong Kong) Limited.